[Events attributable to Vaxzevria vaccine in pregnant women from a first-level hospital in Puebla].

Josafath Alan Huerta-Rojas, Gabriela Bravo-de la Rosa, Jesús Texis-Ramírez, Itari Teresa Reyes-Tobón
{"title":"[Events attributable to Vaxzevria vaccine in pregnant women from a first-level hospital in Puebla].","authors":"Josafath Alan Huerta-Rojas, Gabriela Bravo-de la Rosa, Jesús Texis-Ramírez, Itari Teresa Reyes-Tobón","doi":"10.5281/zenodo.12667969","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2. This disease had a high mortality rate and turned into a pandemic, which is why it was considered a severe public health problem. In this context, pregnant patients were a vulnerable group and, consequently, an effective vaccine was necessary.</p><p><strong>Objective: </strong>To categorize the events attributable to the application of Vaxzevria vaccine in pregnant patients.</p><p><strong>Material and methods: </strong>Retrospective, cross-sectional, descriptive and observational study carried out at No. 55 Family Medicine Unit in Puebla, Puebla. 300 patients between 15 and 44 years of age who received the first dose of Vaxzevria vaccine were included. The Format of Notification of Events Presumably Attributable to Vaccination was reviewed.</p><p><strong>Results: </strong>The most representative general symptoms were headache in 44.3%; fever in 30.7%; asthenia and adynamia in 19.3%; adynamia in 19%, and limitation of movement in 3%. Concerning local symptoms and signs, 23% presented localized pain on the site where the vaccine was administered. Finally, regarding systemic symptoms, 21.7% had arthralgias and 20.7% myalgias.</p><p><strong>Conclusions: </strong>The symptoms and signs were of less severity for pregnant patients, and resolved in a few days, which is why it was safe the administration of Vaxzevria vaccine.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"62 5","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.12667969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2. This disease had a high mortality rate and turned into a pandemic, which is why it was considered a severe public health problem. In this context, pregnant patients were a vulnerable group and, consequently, an effective vaccine was necessary.

Objective: To categorize the events attributable to the application of Vaxzevria vaccine in pregnant patients.

Material and methods: Retrospective, cross-sectional, descriptive and observational study carried out at No. 55 Family Medicine Unit in Puebla, Puebla. 300 patients between 15 and 44 years of age who received the first dose of Vaxzevria vaccine were included. The Format of Notification of Events Presumably Attributable to Vaccination was reviewed.

Results: The most representative general symptoms were headache in 44.3%; fever in 30.7%; asthenia and adynamia in 19.3%; adynamia in 19%, and limitation of movement in 3%. Concerning local symptoms and signs, 23% presented localized pain on the site where the vaccine was administered. Finally, regarding systemic symptoms, 21.7% had arthralgias and 20.7% myalgias.

Conclusions: The symptoms and signs were of less severity for pregnant patients, and resolved in a few days, which is why it was safe the administration of Vaxzevria vaccine.

[普埃布拉一家一级医院的孕妇接种 Vaxzevria 疫苗后发生的事件]。
背景:COVID-19 是由 SARS-CoV-2 引起的严重急性呼吸系统综合征:COVID-19 是由 SARS-CoV-2 引起的严重急性呼吸系统综合征。这种疾病的死亡率很高,并演变成一种大流行病,因此被认为是一个严重的公共卫生问题。在这种情况下,孕妇是易感人群,因此有必要接种有效的疫苗:材料与方法:回顾性、横断面、研究性分析:普埃布拉州普埃布拉市第 55 家庭医学科开展了一项回顾性、横断面、描述性和观察性研究。研究对象包括 300 名接种了第一剂 Vaxzevria 疫苗的 15 至 44 岁患者。对可能与接种疫苗有关的事件通知格式进行了审查:最有代表性的全身症状是:44.3%的人头痛;30.7%的人发烧;19.3%的人气喘和副肾炎;19%的人副肾炎;3%的人活动受限。在局部症状和体征方面,23%的患者在注射疫苗的部位出现局部疼痛。最后,在全身症状方面,21.7%的人有关节痛,20.7%的人有肌痛:怀孕患者的症状和体征较轻,并在几天内缓解,因此接种 Vaxzevria 疫苗是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信